Press Releases

Date Title  
Toggle Summary Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress
– Full Results from Phase 3 ARTEMIS Study Will Be Featured – BRISBANE, Calif. --(BUSINESS WIRE)--May 24, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will present AR101 and patient
Toggle Summary New Study Shows More Than Half of Teens with Peanut Allergy Visited the E.R., More Than One-Third Required Hospitalization Due to Accidental Exposure to Peanut
-- 4 in 10 Teens believe they have a great or very great chance or certainty of dying from accidental exposure -- NEW ORLEANS --(BUSINESS WIRE)--May 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today
Toggle Summary Aimmune to Present at RBC Capital Markets Global Healthcare Conference
BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc.  (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt , will present at the RBC Capital Markets Global
Toggle Summary Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy
- Company Enters into Commercial Supply Agreement for AR101 - BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has been informed by the U.S.
Toggle Summary Aimmune Therapeutics Announces First Quarter 2019 Financial Results and Provides Operational Highlights
Potential FDA approval of AR101 for peanut allergy expected by late January 2020 ; Company on target to be launch-ready in Q4 2019 Submission of marketing application for AR101 in Europe on track for mid-2019, following positive topline results of ARTEMIS European Phase 3 trial Initiation of AR201
Toggle Summary Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
BRISBANE, Calif. --(BUSINESS WIRE)--May 1, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Wednesday, May 8, 2019 , at 4:30 p.m.
Toggle Summary Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference
BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 3, 2019-- Aimmune Therapeutics, Inc.  (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas , M.D., President and Chief Executive Officer, will present at the Needham &
Toggle Summary European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint
-- Company Intends to Submit European MAA in Mid-2019 -- -- Webcast and Conference Call Today at 8:30 a.m. EDT -- BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 25, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies,
Toggle Summary U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy
-- If Approved, AR101 Will Be the First Medicine for This Life-Threatening Condition -- BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that the
Toggle Summary Aimmune Therapeutics to Participate in Three Investor Conferences in March
BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 5, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in three upcoming investor